The Experts in Animal Health

printer friendly

Brakke Consulting’s
Animal Health News & Notes for November 22, 2017
Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon DVM MBA
Brakke Consulting news
Market research
earnings news
J. M. Smucker
Jaguar Health

other news
Creso Pharma
Zhejiang Kingdom Creative Co., Ltd.

Look Before You Leap

Depend on Brakke Consulting to build a market study to meet your company’s needs, whether it is:

• Assessing the feasibility of a new product or technology
• Identifying the opinions and trends of veterinarians, pet owners or producers
• Determining the current market for products

With our in-house database of veterinarians and the ability to custom-tailor surveys of a wide variety of target audiences, we provide reliable insights into this unique industry. We also produce multiclient reports in a number of high-interest animal health market areas. For more information, see our website or call our Dallas office at 972-243-4033.


• Patterson Companies, Inc. reported financial results for the fiscal second quarter ended October 28, 2017. Reported net sales in the Animal Health segment were $824 million, up 2% from last year’s second quarter (+1.4% on a constant currency basis). (PRNewswire)

• Krka reported financial results for the first nine months of 2017. Animal health revenues were EUR 48.4 million ($57.1 million), a 4% decline from the third quarter of 2016. (Animal Pharm)

• Jaguar Health reported results for the third quarter of 2017.  Total revenues were $1.1 million compared to revenues of $50,357 in the third quarter of 2016; animal health revenue was $736,160, of which $33,611 was sales of Neonorm and most of the remainder was collaboration revenue. Net loss before tax was $(7.4) million in the third quarter of 2017 compared to a net loss of $(3.4) million in the comparable prior-year quarter. (company 10-Q)

• The J. M. Smucker Company announced results for the second quarter of fiscal 2018 ended October 31, 2017. Net sales for the US Pet Retail Segment were $552 million, an increase of 4% compared to the comparable prior-year period.  Segment profit was $131 million, an increase of 7%. (company website)

• Zomedica Pharmaceuticals Corp. announced that its registration statement on Form S-1 has been declared effective by the US Securities and Exchange Commission (SEC). Zomedica’s common shares commenced trading on the NYSE American under the symbol “ZOM” at market open on November 21, 2017. The Company will retain its listing on the TSX Venture Exchange (TSX-V). (

• CAMBODIA  Alltech announced it has established its first office in Cambodia to better the producers it is already serving. (

• SPAIN  Bionaturis announced it has signed a license agreement with an undisclosed business for the exclusive registration and commercialization of Bionaturis’ non-prescription products for livestock. The undisclosed international business, which has regional scope, will import, distribute and sell the Bionaturis products, as well as obtaining the marketing authorization, whose ownership will be shared. The agreement has an initial term of three years with automatic renewal of one-year periods and a minimum annual order commitment of EUR 4.77 million ($5.6 million), once the marketing authorization has been obtained. (Animal Pharm)

• CHINA  Creso Pharma announced a strategic partnership and commercial distribution agreement with Zhejiang Kingdom Creative Co., Ltd. The two companies will collaborate to distribute hemp- and cannabis-based products for human and animal health as well as cosmetics, body care and medicinal cannabis products across China. Terms were not disclosed. (

The consultants and staff at Brakke Consulting wish all of our U.S. friends and clients an enjoyable and safe Thanksgiving holiday!

Ron Brakke
Joel Adamson
Cary Christensen
Raymond Collier
Lynn Fondon
Atsuo Hata
Bob Jones
Darrell Klug
Jay Lockhart
John Mannhaupt
Susan Mannhaupt
Jessica Montgomery
Jane Morgan
Kevin Scott
Yuki Ujimasa
John Volk

This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.

For more information about Brakke Consulting’s services and syndicated studies, visit our website at
Brakke Consulting, Inc.
12005 Ford Rd., Suite 530
Dallas, TX  75234    USA


en_USEnglish (United States)